Characterizing Blood Glucose Variability Using New Metrics with Continuous Glucose Monitoring Data

Abstract

Objective:

Glycemic variability contributes to oxidative stress, which has been linked to the pathogenesis of the long-term complications of diabetes. Currently, the best metric for assessing glycemic variability is mean amplitude of glycemic excursion (MAGE); however, MAGE is not in routine clinical use. A glycemic variability metric in routine clinical use could potentially be an important measure of overall glucose control and a predictor of diabetes complication risk not detected by glycosylated hemoglobin (A1C) levels. This study aimed to develop and evaluate new automated metrics of glycemic variability that could be routinely applied to continuous glucose monitoring (CGM) data to assess and enhance glucose control.

Method:

Individual 24 h CGM tracings from our clinical diabetes research database were scored for MAGE and two additional metrics designed to compensate for aspects of variability not captured by MAGE: (1) number of daily glucose fluctuations >75 mg/dl that leave the normal range (70–175 mg/dl), or excursion frequency, and (2) total daily fluctuation, or distance traveled. These scores were used to train machine learning algorithms to recognize excessive variability based on physician ratings of daily CGM charts, producing a third metric of glycemic variability: perceived variability. Finger stick A1C (average) and serum 1,5-anhydroglucitol (postprandial) levels were used as clinical markers of overall glucose control for comparison.

Results:

Mean amplitude of glycemic excursion, excursion frequency, and distance traveled did not adequately quantify the glycemic variability visualized by physicians who evaluated the daily CGM plots. A naive Bayes classifier was developed that characterizes CGM tracings based on physician interpretations of tracings. Preliminary results suggest that the number of excessively variable days, as determined by this naive Bayes classifier, may be an effective way to automatically assess glycemic variability of CGM data. This metric more closely reflects 90-day changes in serum 1,5-anhydroglucitol levels than does MAGE.

Conclusion:

We have developed a new automated metric to assess overall glycemic variability in people with diabetes using CGM, which could easily be incorporated into commercially available CGM software. Additional work to validate and refine this metric is underway. Future studies are planned to correlate the metric with both urinary 8-iso-prostaglandin F2 alpha excretion and serum 1,5-anhydroglucitol levels to see how well it identifies patients with high glycemic variability and increased markers of oxidative stress to assess risk for long-term complications of diabetes.

Keywords

blood glucose measurement continuous glucose monitoring glycemic control glycemic variability machine learning naive Bayes classifiers

References

Brownlee

. Biochemistry and molecular cell biology of diabetes complications. Nature. 2001; 414 (6865): 813–20.

Brownlee

. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54 (6): 1615–25.

Kilpatrick

Rigby

Atkin

. For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med. 2010; 27 (8): 868–71.

Ceriello

Ihnat

. ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med. 2010; 27 (8): 862–7.

Monnier

Mas

Ginet

Michel

Villon

Cristol

Colette

. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006; 295 (14): 1681–7.

Monnier

Colette

. Glycemic variability: should we and can we prevent it? Diabetes Care. 2008; 31 Suppl 2: S150–4.

Kilpatrick

Rigby

Atkin

. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2006; 29 (7): 1486–90.

Hirsch

Brownlee

. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005; 19 (3): 178–81.

Service

Molnar

Rosevear

Ackerman

Gatewood

Taylor

. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970; 19 (9): 644–55.

10.

McDonnell

Donath

Vidmar

Werther

Cameron

. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005; 7 (2): 253–63.

11.

Kovatchev

Otto

Cox

Gonder-Frederick

Clarke

. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006; 29 (11): 2433–8.

12.

Rodbard

. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther. 2009; 11 (9): 551–65.

13.

Rodbard

. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther. 2009; 11 Suppl 1: S55–67.

14.

Marling

Shubrook

Schwartz

. Toward case-based reasoning for diabetes management: a preliminary clinical study and decision support system prototype. Comput Intel. 2009; 25 (3): 165–79.

15.

Schwartz

Shubrook

Marling

. Use of case-based reasoning to enhance intensive management of patients on insulin pump therapy. J Diabetes Sci Technol. 2008; 2 (4): 603–11.

16.

Schwartz

Vernier

Shubrook

Marling

. Evaluating the automated blood glucose pattern detection and case-retrieval modules of the 4 Diabetes Support System. J Diabetes Sci Technol. 2010; 4 (6): 1563–9.

17.

Buse

Freeman

Edelman

Jovanovic

McGill

. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther. 2003; 5 (3): 355–63.

18.

Morrow

Hill

Burk

Nammour

Badr

Roberts

2nd . A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990; 87 (23): 9383–7.

19.

Roberts

Morrow

. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000; 28 (4): 505–13.

20.

Mastrototaro

Shin

Marcus

Sulur

; STAR 1 Clinical Trial Investigators. The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol Ther. 2008; 10 (5): 385–90.

21.

Bequette

B. W.

Continuous glucose monitoring: real-time algorithms for calibration, filtering, and alarms. J Diabetes Sci Technol. 2010; 4 (2): 404–18.

22.

Sparacino

Facchinetti

Maran

Cobelli

. Continuous glucose monitoring time series and hypo/hyperglycemia prevention: requirements, methods, open problems. Curr Diabetes Rev. 2008; 4 (3): 181–92.

23.

Witten

Frank

Trigg

Hall

Holmes

Cunningham

. Weka: practical machine learning tools and techniques with Java implementations. In: Proc ICONIP/ANZIIS/ANNES99: Future Directions for Intelligent Systems and Information Sciences, Dunedin, New Zealand, November 1999, 192–6.